• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由p53-GYS1反馈回路介导的糖原储备导致卵巢透明细胞癌产生铂耐药性。

Glycogen stores mediated by the p53-GYS1 feedback circuit engenders platinum resistance in ovarian clear cell carcinoma.

作者信息

Liang Hao-Yu, Luo Rong-Zhen, Deng Ru, Chen Shi-Lu, Liu Xuan, Yang Xia, Wei Li-Jun, Wei Zong-Qiang, Wu Li-Yan, Shen Hui-Min, Yun Jing-Ping, Liu Li-Li

机构信息

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

出版信息

Cell Death Differ. 2025 Apr 11. doi: 10.1038/s41418-025-01500-z.

DOI:10.1038/s41418-025-01500-z
PMID:40210982
Abstract

Ovarian cancer (OC) is a highly fatal and refractory malignancy affecting women, and platinum resistance remains a major clinical dilemma. Compared with other OC subtypes, ovarian clear cell carcinoma (OCCC) frequently exhibits increased platinum refractoriness, accompanied by increased glycogen levels, which promotes clear-cell morphology, and wild-type p53. However, the roles of these factors in platinum resistance of OCCC are unclear. Here, we investigated whether glycogen promotes OCCC resistance to platinum agents and reported that GYS1, a rate-limiting enzyme in glycogen synthesis, is clinically associated with poor prognosis and chemoresistance in OCCC. Mechanistically, p53 promotes GYS1 breakdown via the upregulation of RNF144a, whereas GYS1 induces the reversal of p53 ubiquitination and degradation by competitively binding to USP14, forming a positive feedback circuit. Under platinum stress, the accumulated glycogen is mobilized by the p53/GYS1 feedback circuit, which fuels energetic NADPH production, resulting in resistance to disulfidptosis and increased platinum resistance in OCCC. Collectively, our findings identify glycogen as a contributor to OCCC platinum resistance and elucidate the underlying mechanisms, highlighting a crucial p53/GYS1 positive feedback loop.

摘要

卵巢癌(OC)是一种影响女性的高致死性和难治性恶性肿瘤,铂耐药仍然是一个主要的临床难题。与其他OC亚型相比,卵巢透明细胞癌(OCCC)经常表现出更高的铂难治性,同时伴有糖原水平升高,这促进了透明细胞形态的形成,以及野生型p53。然而,这些因素在OCCC铂耐药中的作用尚不清楚。在此,我们研究了糖原是否促进OCCC对铂类药物的耐药性,并报告糖原合成中的限速酶GYS1在临床上与OCCC的不良预后和化疗耐药相关。机制上,p53通过上调RNF144a促进GYS1降解,而GYS1通过竞争性结合USP14诱导p53去泛素化和降解的逆转,形成一个正反馈回路。在铂应激下,积累的糖原通过p53/GYS1反馈回路被动员起来,这为活跃的NADPH产生提供能量,导致对二硫化物诱导的细胞死亡产生抗性,并增加OCCC中的铂耐药性。总体而言,我们的研究结果确定糖原是OCCC铂耐药的一个促成因素,并阐明了潜在机制,突出了关键的p53/GYS1正反馈回路。

相似文献

1
Glycogen stores mediated by the p53-GYS1 feedback circuit engenders platinum resistance in ovarian clear cell carcinoma.由p53-GYS1反馈回路介导的糖原储备导致卵巢透明细胞癌产生铂耐药性。
Cell Death Differ. 2025 Apr 11. doi: 10.1038/s41418-025-01500-z.
2
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.聚乙二醇化脂质体阿霉素用于复发性上皮性卵巢癌
Cochrane Database Syst Rev. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2.
3
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.改变铂类敏感复发性卵巢癌的治疗模式:从铂类双联到非铂类双联,并加入抗血管生成化合物。
Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S63-7. doi: 10.1111/IGC.0b013e3181c104fa.
4
A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.一种新型的CD71 Centyrin:Gys1小干扰RNA偶联物可降低庞贝病小鼠模型中的糖原合成及糖原水平。
Mol Ther. 2025 Jan 8;33(1):235-248. doi: 10.1016/j.ymthe.2024.11.033. Epub 2024 Nov 26.
5
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.厄洛替尼或吉非替尼治疗铂类预处理复发的非小细胞肺癌和卵巢癌:系统评价。
Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24.
6
Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models.卵巢癌细胞系和同基因模型中的细胞内在铂反应以及相关的遗传和基因表达特征。
bioRxiv. 2024 Jul 29:2024.07.26.605381. doi: 10.1101/2024.07.26.605381.
7
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗:一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
8
Aspects of Genetic Diversity, Host Specificity and Public Health Significance of Single-Celled Intestinal Parasites Commonly Observed in Humans and Mostly Referred to as 'Non-Pathogenic'.人类常见且大多被称为“非致病性”的单细胞肠道寄生虫的遗传多样性、宿主特异性及公共卫生意义
APMIS. 2025 Sep;133(9):e70036. doi: 10.1111/apm.70036.
9
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
10
Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab.优化铂耐药性卵巢透明细胞癌的治疗:吉西他滨及与贝伐单抗联合治疗的疗效
Cancer. 2025 Sep 1;131(17):e70071. doi: 10.1002/cncr.70071.

本文引用的文献

1
Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes.上皮性卵巢癌的蛋白质组学特征分析明确了不同组织学亚型的分子特征和治疗靶点。
Nat Commun. 2023 Nov 28;14(1):7802. doi: 10.1038/s41467-023-43282-3.
2
Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.Gys1 反义疗法可预防拉佛拉病小鼠模型中的致病聚集物和癫痫样放电。
Neurotherapeutics. 2023 Oct;20(6):1808-1819. doi: 10.1007/s13311-023-01434-9. Epub 2023 Sep 12.
3
Clinical and translational advances in ovarian cancer therapy.
卵巢癌治疗的临床和转化进展。
Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31.
4
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.靶向糖原合酶 1 揭示了三阴性乳腺癌的代谢脆弱性。
J Exp Clin Cancer Res. 2023 Jun 6;42(1):143. doi: 10.1186/s13046-023-02715-z.
5
New therapies for clear cell ovarian carcinoma.用于透明细胞卵巢癌的新疗法。
Int J Gynecol Cancer. 2023 Mar 6;33(3):385-393. doi: 10.1136/ijgc-2022-003704.
6
What is cancer metabolism?癌症代谢是什么?
Cell. 2023 Apr 13;186(8):1670-1688. doi: 10.1016/j.cell.2023.01.038. Epub 2023 Feb 28.
7
Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis.细胞骨架对二硫键压力的脆弱性介导了二硫键细胞凋亡。
Nat Cell Biol. 2023 Mar;25(3):404-414. doi: 10.1038/s41556-023-01091-2. Epub 2023 Feb 6.
8
Drugging p53 in cancer: one protein, many targets.在癌症中靶向 p53:一种蛋白,多个靶点。
Nat Rev Drug Discov. 2023 Feb;22(2):127-144. doi: 10.1038/s41573-022-00571-8. Epub 2022 Oct 10.
9
Hepatic p53 is regulated by transcription factor FOXO1 and acutely controls glycogen homeostasis.肝 p53 通过转录因子 FOXO1 调控,并急性控制糖原动态平衡。
J Biol Chem. 2022 Sep;298(9):102287. doi: 10.1016/j.jbc.2022.102287. Epub 2022 Jul 20.
10
Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.靶向 p53-MDM2 相互作用的小分子抑制剂:从临床试验中的 MDM2 抑制剂中获得的启示。
J Hematol Oncol. 2022 Jul 13;15(1):91. doi: 10.1186/s13045-022-01314-3.